Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm
01:38pm, Friday, 24'th Jan 2025
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE) breach
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
10:06am, Tuesday, 14'th Jan 2025
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more s
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (N
Biogen Offers to Buy Remaining Stake in Sage Therapeutics
04:01pm, Monday, 13'th Jan 2025
Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.
Sage Therapeutics shares surge on unsolicited takeover bid from Biogen
11:51am, Monday, 13'th Jan 2025
Sage Therapeutics (NASDAQ:SAGE) stock soared after the firm announced that it had received an unsolicited takeover bid from Biogen Inc (NASDAQ:BIIB, ETR:IDP). Biogen has proposed to acquire all of S
Sage takeout bid implies zero enterprise value, says Mizuho
11:31am, Monday, 13'th Jan 2025
Sage Therapeutics + Biogen -0.36 (-0.24%)
Sage Therapeutics Stock Headed for Best Day in 5 Years
11:16am, Monday, 13'th Jan 2025
Biotech stock Sage Therapeutics Inc (NASDAQ:SAGE) is skyrocketing today, up 33.7% to trade at $7.42 at last glance, after Biogen's (BIIB) proposed takeover, which the company said on Friday it would c
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
10:40am, Monday, 13'th Jan 2025
Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (N
Biogen bid for Sage does not change narrative, says BMO Capital
09:39am, Monday, 13'th Jan 2025
Biogen -1.98 (-1.31%) Sage Therapeutics -0.29 (-4.96%)
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
09:38am, Monday, 13'th Jan 2025
On Friday, Sage Therapeutics Inc. SAGE confirmed that Biogen Inc. BIIB submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned
Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist
09:35am, Monday, 13'th Jan 2025
Sage Therapeutics -0.29 (-4.96%) Biogen -1.98 (-1.31%)
BofA moves to No Rating on Sage Therapeutics after Biogen bid
09:29am, Monday, 13'th Jan 2025
Sage Therapeutics -0.29 (-4.96%) Biogen -1.98 (-1.31%)
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
07:24am, Monday, 13'th Jan 2025
The biopharmaceutical company says its board of directors will now review and evaluate the offer from Biogen.
Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference
06:00pm, Sunday, 12'th Jan 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company's strategic focus areas for 2025 at the 43r
